Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (clinicaltrials.gov) - Oct 15, 2026 - P2 | N=35 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2026 ➔ Jun 2027 | Trial primary completion date: Nov 2026 ➔ Jun 2027
Trial completion date • Trial primary completion date • Endocrine Cancer • Genito-urinary Cancer • Genitourinary Neuroendocrine Carcinoma • Neuroendocrine Carcinoma • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CHGA • PTEN • RB1 • SYP • TP53
|